Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Eli Lilly and Company (NYSE:LLY) is included in our list of the 11 Best Rebound Stocks to Buy According to Hedge Funds. On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

COMMENT: The astronomical rise in weight-loss drug prices caused by Trump’s tariffs could have a significant – and dangerous ...

Daiwa analyst Narumi Nakagiri downgraded Eli Lilly (LLY) to Neutral from Outperform with a $700 price target Published first on TheFly – the ...

Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards ...

Structure Therapeutics has dropped over 55% as its GLP-1 pill targets obesity, yet analysts remain bullish with high price ...

Steroid dealers using social media and beauty salons to sell cheap Chinese copies of weight-loss drugs, experts warn ...